Effects of 3 months of treatment with empagliflozin on left ventricle global longitudinal strain and myocardial mechano-energetic effiency

Purpose Sodium glucose transporter-2 (SGLT-2) inhibitors are employed in the treatment of cardiovascular diseases such as heart failure and coronary artery disease. In the present study, we aimed to investigate how Empagliflozin in SGLT 2 inhibitors affects cardiac contraction and pump efficiency in patients who have Diabetes Mellitus (DM) without cardiovascular disease. Methods The conventional echocardiographic records and biochemical values of 62 patients who had DM without a history of cardiovascular disease were evaluated before using Empagliflozin. The myocardial mechano-energetic (MME) activity and index, and global longitudinal strain (GLS) were also calculated. After 3 months of Empagliflozin use, the tests were repeated and compared with previous data. A p Left ventricular GLS and MME efficiency were found to be significantly higher after treatment (-17.71 +/- 2.12, -19.15 +/- .71; p < .001 and 62.14 +/- 18.21, 72.24 +/- 26.57; p: .019). Conclusion An increase was detected in left ventricular longitudinal strain and MME efficiency after using Empagliflozin for 3 months in patients with DM. This result suggests that Empagliflozin improves left ventricular pump efficiency and contraction.

Automated summary

In patients with diabetes but no cardiovascular disease, the use of Empagliflozin for 3 months led to significant increases in left ventricular GLS and MME efficiency, indicating an improvement in cardiac pump efficiency and contraction.